Literature DB >> 6461156

Tiapride in the treatment of Huntington's chorea.

R A Roos, O J Buruma, G W Bruyn, B Kemp, E A van der Velde.   

Abstract

Twenty-two patients with Huntington's chorea were investigated in a double-blind controlled cross-over trial. The effect was measured by counting the number of involuntary movements from video-recordings and by a Doppler-radar device. Besides these methods, subjective assessments were made on analogue scales by patients, family, nurses and attendant doctors. The quantitative methods revealed no significant diminution of the involuntary movements in the Tiapride therapy period. The subjective evaluation turned out to be useless because of many inconsistent answers.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6461156     DOI: 10.1111/j.1600-0404.1982.tb03060.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  11 in total

1.  Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease.

Authors:  T Norman; E Chiu; R H James; M S Gregory
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease.

Authors:  R A Roos; E J de Haas; O J Buruma; F A de Wolff
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  The Many Faces of Huntington's Chorea Treatment: The Impact of Sudden Withdrawal of Tiapride after 40 Years of Use and a Systematic Review.

Authors:  Stephanie Feleus; Malu van Schaijk; Raymund A C Roos; Susanne T de Bot
Journal:  J Pers Med       Date:  2022-04-06

Review 4.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

5.  Assessment of the therapeutic range of tiapride in patients with tardive dyskinesia.

Authors:  R A Roos; E A Van der Velde; O J Buruma; F A de Wolff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

6.  A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.

Authors:  N Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

Review 7.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 8.  Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

Authors:  Emma M Coppen; Raymund A C Roos
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

9.  Aripiprazole in the treatment of Huntington's disease: a case series.

Authors:  Andrea Ciammola; Jenny Sassone; Clarissa Colciago; Niccolò E Mencacci; Barbara Poletti; Andrea Ciarmiello; Ferdinando Squitieri; Vincenzo Silani
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

Review 10.  Old Drugs as New Treatments for Neurodegenerative Diseases.

Authors:  Fernando Durães; Madalena Pinto; Emília Sousa
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.